Europe
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces its unaudited interim results for the six months ended 30 June 2019.
According to a new study carried out at the University of Eastern Finland, the distribution of drug molecules within the brain can be improved by utilizing LAT1, which is expressed highly in the brain.
Research from the Wellcome Sanger Institute, GSK and Biogen, under the Open Targets initiative, has shown that thousands of differences in DNA between individuals, associated with immune diseases, are linked with the switching-on of a specific subtype of immune cells.
During the European Society of Medical Oncology (ESMO) Congress, to be held from September 27th to October 1st in Barcelona, the recent results of the lurbinectedin trial for the treatment of progressive malignant pleural mesothelioma, carried out by SAKK in collaboration with PharmaMar, will be presented.
BioMed X announced today the completion of their first research collaboration project with Roche Diagnostics in the field of nanomaterial-based biosensors for near patient testing.
Faron announces its unaudited interim results for the six months ended 30 June 2019.
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platforms, will present the anti-cancer impact of its TheraT® technology in four poster presentations at the CICON Cancer Immunotherapy Conference taking place September 25-28 in Paris.
Clinigen Group plc, the global pharmaceuticals and services group, has published its full year results for the year ended 30 June 2019.
It was a moderately busy week for clinical trial news. Here’s a look.
Companies from across the globe share updates on their business and pipelines.
PRESS RELEASES